Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Maria L, Naylor"'
Autor:
Saira Z Sheikh, Maria L Naylor, Lasair O’Callaghan, Lina Sladkeviciute, Janine Gaiha-Rohrbach, Cherie Butts
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d726b45a9cbc4235b29a7cefa321754c
Autor:
Thomas F. Scott, Ray Su, Kuangnan Xiong, Arman Altincatal, Carmen Castrillo-Viguera, Maria L. Naylor
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Peginterferon beta-1a and glatiramer acetate (GA) are approved first-line therapies for the treatment of relapsing forms of multiple sclerosis, but their therapeutic efficacy has not been compared directly. Methods: Clinical outcomes at 2
Externí odkaz:
https://doaj.org/article/920ebc3cf83942ba9a92b1ba387c13f6
Autor:
Yuan Zhao, Kun Chen, Nancy Ramia, Sangeeta Sahu, Achint Kumar, Maria L. Naylor, Li Zhu, Himanshu Naik, Cherié L. Butts
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated i
Externí odkaz:
https://doaj.org/article/e34c67943f41454384c25cf085c4bbfd
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: No evidence of disease activity (NEDA) is a composite measurement, incorporating clinical and magnetic resonance imaging (MRI) elements of disease activity to sensitively evaluate the therapeutic efficacy of treatments for relapsing–rem
Externí odkaz:
https://doaj.org/article/8dc73721ee4e4953a23109e4e4cc0c15
Autor:
Scott D. Newsome, Thomas F. Scott, Douglas L. Arnold, Gereon Nelles, Serena Hung, Yue Cui, Shulian Shang, Maria L. Naylor, Marcelo Kremenchutzky
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 11 (2018)
Background: ADVANCE was a phase III trial of the efficacy and safety of subcutaneous peginterferon beta-1a 125 µg every 2 or 4 weeks in patients with relapsing-remitting multiple sclerosis (RRMS). ATTAIN was a 2-year extension study of ADVANCE. The
Externí odkaz:
https://doaj.org/article/0d6383108a324594a228068074ed26f7
Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach
Autor:
Claudia Röder, Michelle Allan, Colleen Harris, Carol Chieffe, Maria L. Naylor, Piet Eelen, Sarah White, Catherine Mouzawak
Publikováno v:
Neurology and Therapy
Introduction Injection site reactions (ISRs) and flu-like symptoms (FLS) are common in patients with relapsing forms of multiple sclerosis (MS) treated with peginterferon beta-1a. The purpose of this Delphi analysis was to explore peginterferon beta-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23dff015807627ec052ff3e75c87935c
https://doi.org/10.1007/s40120-021-00238-3
https://doi.org/10.1007/s40120-021-00238-3
Autor:
Catrinel Popescu, Anthony T. Reder, Maha Radhakrishnan, Aaron Berdofe, Anjali Nagpal, Karen Smirnakis, Rajani Rajbhandari, Maria L. Naylor, Arman Altincatal, Carl de Moor, Michelle Kim, Alfred Sandrock, Eunice Jung, Diego Centonze
Publikováno v:
CNS Drugs
Background Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5576e85d38ac70fba9d37d534dae3c6
http://europepmc.org/articles/PMC7980129
http://europepmc.org/articles/PMC7980129
Autor:
Gary Cutter, Richard A Rudick, Carl de Moor, Carol M Singh, Elizabeth Fisher, Thijs Koster, Fred D Lublin, Jerry S Wolinsky, Henry McFarland, Steven Jacobson, Maria L Naylor
Publikováno v:
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 9:205521732311694
Background CombiRx was a randomized, double-blind, placebo-controlled phase 3 trial in treatment-naive relapsing-remitting multiple sclerosis (RRMS) patients randomized to intramuscular interferon beta-1a (IM IFN beta-1a), glatiramer acetate (GA), or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cb1f57c70859fd50f29bd675061f657
https://doi.org/10.1177/20552173231169463
https://doi.org/10.1177/20552173231169463
BackgroundBlack/African-American participants are underrepresented in clinical trials but can experience a greater burden of disease, such as multiple sclerosis, than other racial groups in the United States. A phase 1, open-label, 2-period crossover
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2082b0b6e804a8630d6a0133a2d8e89a
https://doi.org/10.1101/2022.04.01.22272847
https://doi.org/10.1101/2022.04.01.22272847
Autor:
Jeffrey A Cohen, Robert A Bermel, Cynthia I Grossman, Carrie M Hersh, Megan Hyland, Ellen M Mowry, Robert Naismith, Maria L Naylor, Jacqueline Nicholas, Rajani Rajbhandar, Carol M Singh, Mar Tintorè, Ana Zabalza, Tjalf Ziemssen, James R Williams, Xavier Montalban
Publikováno v:
Scientia
Multiple sclerosis; SARS-COV-2 vaccination; Humoral immune response Esclerosis múltiple; Vacunación SARS-COV-2; Respuesta inmune humoral Esclerosi múltiple; Vacunació SARS-COV-2; Resposta immune humoral Background: The impact of multiple sclerosi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3806a3b03e94dbc7c0718ee33ac2442
https://pubmed.ncbi.nlm.nih.gov/34994577
https://pubmed.ncbi.nlm.nih.gov/34994577